pitchbook.com
Open in
urlscan Pro
34.110.234.203
Public Scan
Submitted URL: https://url6380.news.pitchbook.com/ls/click?upn=-2B0Jlug6i80mluh5Xp2-2BZsfdSR-2BbC0M2D2Pkba6hdCexEZchbkBxCmkQgblVPhk7jPDwX6ZMZYfGUB...
Effective URL: https://pitchbook.com/profiles/company/465379-39
Submission: On May 08 via api from US — Scanned from DE
Effective URL: https://pitchbook.com/profiles/company/465379-39
Submission: On May 08 via api from US — Scanned from DE
Form analysis
1 forms found in the DOM/profiles/search
<form action="/profiles/search" class="search-form search-form_focused float-right-XL align-right" role="search" __bizdiag="113" __biza="WJ__">
<input type="text" name="q" value="" maxlength="200" aria-label="Search" class="search-form__input" placeholder="Search profile previews">
<button type="submit" aria-label="Search button" role="button" class="btn-search search-form__submit"></button>
<span data-btn-search-collapsed="" class="XL-0 d-block-XS icon-profile-close secondary-text search-form__close px-xl-10 py-xl-5"></span>
</form>
Text Content
* Request a free trial Log in * Products * Solutions * Data * News & Analysis * About * Blog Log in Request a free trial CONVERGENT THERAPEUTICS This is a profile preview from the PitchBook Platform. Request a free trial * Overview * Timeline * Valuation & Funding * Cap Table * Comparisons * Competitors * Research & Analysis * Patents * Team * Board Members * Service Providers * Signals * Investors * Lead Partners on Deals * Acquisitions * Subsidiaries * Exits CONVERGENT THERAPEUTICS OVERVIEW Update this profile * Founded * 2020 * Status * PRIVATE * Employees * 5 * Latest Deal Type * SERIES A1 * Latest Deal Amount * $90M * Investors * 3 CONVERGENT THERAPEUTICS GENERAL INFORMATION Description Operator of a clinical-stage biotechnology company intended to explore the full potential of dual-targeted combination strategies to treat cancer. The company has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens by leveraging targeting agents with different bio-distributions, such as monoclonal antibodies, ligands and supra-additive therapeutic doses, enabling medical professionals to provide effective cancer treatment to its patients. Contact Information Website www.convergentrx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Biotechnology Primary Office * Cambridge, MA * United States +1 (631) 000-0000 CONVERGENT THERAPEUTICS TIMELINE 202120222023 Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth WANT DETAILED DATA ON 3M+ COMPANIES? What you see here scratches the surface Request a free trial WANT TO DIG INTO THIS PROFILE? We’ll help you find what you need Learn more CONVERGENT THERAPEUTICS VALUATION & FUNDING Deal Type Date Amount Raised to Date Post-Val Status Stage 3. Early Stage VC (Series A1) 03-May-2023 $90M 0000 00000 Completed Pre-Clinical Trials 2. Early Stage VC (Series A2) 08-Apr-2022 00.00 000 0000 Completed Pre-Clinical Trials 1. Early Stage VC (Series A3) $5.5M $5.5M 000.00 Completed Pre-Clinical Trials To view Convergent Therapeutics’s complete valuation and funding history, request access » CONVERGENT THERAPEUTICS CAP TABLE Stock # of Shares Authorized Par Value Dividend Rate (%) Original Issue Price Liquidation Liquidation Pref. Multiple Conversion Price % Owned Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000 Series A-3 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000 Series A-2 2,801,467 $0.001000 6% $1.24 $1.24 1x $1.24 2.71% To view Convergent Therapeutics’s complete cap table history, request access » CONVERGENT THERAPEUTICS EXECUTIVE TEAM (3) Update this profile Name Title Board Seat Contact Info Alex Brown Chief Operating Officer Neil Bander MD Co-Founder & Chief Scientific Advisor Philip Kantoff Co-Founder, Chief Executive Officer and Chief Medical Officer To view Convergent Therapeutics’s complete executive team members history, request access » CONVERGENT THERAPEUTICS SIGNALS Growth Rate 0.80% Weekly Growth Weekly Growth 0.80%, 93rd % -35.5%. 530% Size Multiple 219x Median Size Multiple 219x, 100th %ile 0.00x 0.95x. 413Kx Key Data Points Twitter Followers 5.5k Similarweb Unique Visitors 15.0K Majestic Referring Domains 314 PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach. Request a free trial CONVERGENT THERAPEUTICS INVESTORS (3) Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info OrbiMed PE/Buyout Minority 000 0000 000000 0 RA Capital Management Hedge Fund Minority 000 0000 000000 0 The Invus Group PE/Buyout Minority 000 0000 000000 0 To view Convergent Therapeutics’s complete investors history, request access » Ready to get started? Request a free trial Products * PitchBook Desktop * PitchBook Mobile * CRM Integration * Excel Plugin * Chrome Extension * Direct Data * Institutional Research Group * Morningstar Institutional Equity Research * Product Releases PitchBook for * Private Market Valuations * Venture Capital * Private Equity * Hedge Funds * Startups Profile Previews Solutions * Private Market Intel * Fundraising * Deal Sourcing * Due Diligence * Business Development * Networking * Deal Execution * Benchmarking * Asset Allocation Blog Webinars Video Library Data * Companies * Investors * Deals * M&A * Limited Partners * Funds * Financials * Advisors * Professionals * Debt * Lenders * Data Operations Leveraged Commentary and Data News & analysis * Reports * Newsletter * Advertise * Research & Analysis Team About * Customer Success * Client Testimonials * What Sets Us Apart * Press Inquiries * Partnerships * Careers Follow us * * * * * US Headquarters * +1 (206) 623.1986 * 901 Fifth Avenue * Suite 1200 * Seattle, WA 98164 European Headquarters * +44 (0) 20 8037.2308 * 1st Floor Saffron House * 6-10 Kirby Street * London EC1N 8TS * United Kingdom Asia-Pacific Headquarters * 80 Raffles Place * #41-01 UOB Plaza 1 * Singapore 048624 Contact Us * info@pitchbook.com * Request Research * Profile Request * Deal Submission * GDPR Compliance Follow us * * * * * © 2023 PitchBook. Win what’s next. All rights reserved. * Terms of Use * Privacy Policy We need your consent to proceed to PitchBook Our site uses cookies and other technologies to improve your experience and understand how you and other visitors use our site. You can configure your preferences at any time using the cookie policy tool. When you access our site, the companies listed in our cookie policy will use cookies on our site. Agree and Enter Close ✖